



Insights Into Multiple Myeloma (MM) – Southeast

Friday, March 10, 2023

Speaker: Jonathan Kaufman, MD
 Moderator: Keren Sturtz, MD

AGENDA

Time (ET)	Topic
2.00 PM – 2.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • Baseline ARS questions
2.15 PM – 3.25 PM (30-min presentation; 40-min discussion)	Initial Treatment for Newly Diagnosed Disease <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Induction therapy in transplant-eligible and -ineligible patients <ul style="list-style-type: none"> ▪ Transplant eligibility ▪ Selection of induction therapy for transplant-ineligible MM <ul style="list-style-type: none"> • Dara-Rd vs VRd • Dara-Rd first-line therapy vs second-line use ▪ Selection of induction therapy for transplant-eligible MM <ul style="list-style-type: none"> • Triplet vs quadruplet therapy ▪ AE management – Future use of CAR T-cell therapy in treatment of newly diagnosed MM <ul style="list-style-type: none"> ▪ Ciltacabtagene autoleucel (cilta-cel) <ul style="list-style-type: none"> • CARTITUDE-5 • Reaction and discussion
3.25 PM – 3.35 PM (10 min)	Break

<p>3.35 PM – 4.45 PM (30-min presentation; 40-min discussion)</p>	<p>Treatment of Relapsed/Refractory (R/R) Disease</p> <ul style="list-style-type: none"> • ARS questions • Overview of current data <ul style="list-style-type: none"> – Optimal approach for patients at first relapse – Approach to treatment of patients who have disease progression after ≥2 prior regimens – Impact of prior treatment, patient characteristics, and residual toxicities – Anti-CD38 regimens <ul style="list-style-type: none"> ▪ Daratumumab based <ul style="list-style-type: none"> • CANDOR trial ▪ Isatuximab based <ul style="list-style-type: none"> • IKEMA trial – Focus on emerging options <ul style="list-style-type: none"> ▪ BCMA-targeting ADCs <ul style="list-style-type: none"> • MEDI2228 ▪ Anti-BCMA CAR T-cell therapies <ul style="list-style-type: none"> • Idecabtagene vicleucel (ide-cel) • Ciltacabtagene autoleucel (cilta-cel) <ul style="list-style-type: none"> – CARTITUDE-1 – CARTITUDE-4 ▪ BCMA-targeting bispecific antibodies <ul style="list-style-type: none"> • Elranatamab <ul style="list-style-type: none"> – MagnetisMM-3 (ASH 2022 updates) • Teclistamab <ul style="list-style-type: none"> – MajesTEC-1 trial and FDA approval ▪ Additional investigational directions <ul style="list-style-type: none"> • Talquetamab (GPRC5D × CD3) <ul style="list-style-type: none"> – MonumentAL-1 (ASH 2022) – MonumentAL-5 • Reaction and discussion
<p>4.45 PM – 5.00 PM (15 min)</p>	<p>Key Takeaways and Meeting Evaluation</p>